Sin spam. Cancela en cualquier momento.
Análisis de Pureza HPLC
GHRP-2
CAS: 158861-67-7
Estudiado para la máxima secreción de GH en la clase GHRP
GHRP-2 is a research peptide in the growth hormone / gh secretagogues category. GHRP-2 is a synthetic hexapeptide that stimulates GH release by acting as an agonist at the ghrelin receptor (GHSR-1a) on pituitary somatotrophs. MiPeptidos offers GHRP-2 in 3 sizes with 99.5% verified purity and full analytical documentation.
- Strongest GH release available
- Rapid muscle recovery
- Increased appetite for gains
- Better sleep depth
Studies report a strong GH pulse and increased appetite within 30-60 minutes of first use. By weeks 3-6, research suggests IGF-1 levels rise 30-60% above baseline, recovery accelerates dramatically, and lean mass gains become measurable. A typical protocol runs 6-8 weeks.
$15.29/vial · Everything you need to start
Sin spam. Cancela en cualquier momento.
Análisis de Pureza HPLC
Maximum GH Output.
8-week high-potency secretagogue protocol for peak growth hormone release
GHRP-2 (Growth Hormone Releasing Peptide-2, also known as Pralmorelin) is a synthetic hexapeptide that acts as a potent agonist of the ghrelin receptor (GHSR-1a) on pituitary somatotrophs. It is one of the strongest GH secretagogues available, producing robust, dose-dependent GH release that has been validated in multiple clinical trials.
Resultados Publicados
Revisado por ParesResultados cuantificables de investigación clínica publicada.
Lo que Dicen los Expertos
4 MédicosProfesionales e investigadores líderes que han estudiado y prescrito este péptido.
Dr. Cyril Bowers
Professor of Endocrinology, Tulane University
Discoverer of growth hormone-releasing peptides. Pioneered the GHRP field. Multiple patents on GH secretagogues.
GHRP-2 is the most potent GHRP for growth hormone release. When combined with GHRH, it produces synergistic GH secretion that far exceeds either stimulus alone.
1–2 mcg/kg IV or subcutaneous for maximal GH release. Combined with GHRH analog for synergistic effect. Lower doses (100 mcg) still produce clinically meaningful GH pulses.
Fuente: Bowers CY (1998) J Clin Endocrinol Metab; Multiple publications on GHRPs
Dr. William Seeds
Founder, SSRP Institute
40+ years in cellular and molecular medicine. Author of 'Peptide Protocols: Volume 1'.
GHRP-2 produces the strongest GH pulse of any peptide secretagogue. But that potency comes with appetite stimulation and modest cortisol elevation — so it's not for everyone.
100–300 mcg subcutaneous 2–3 times daily. Combine with CJC-1295 for maximum synergy. Use shorter cycles (6–8 weeks) than ipamorelin due to cortisol effects.
Fuente: Peptide Protocols: Volume 1 (ISBN: 978-0578624358)
Dr. Michael Scally
Endocrinologist, HPT Recovery Specialist
Known for pioneering hormonal recovery protocols. Extensive clinical experience with GH secretagogues in post-cycle therapy and hormone restoration.
GHRP-2 is incredibly reliable for GH stimulation. It was approved as a diagnostic agent in Japan for exactly this reason — it produces consistent, predictable GH release.
100–200 mcg subcutaneous, 2–3 times daily. Cycle 6–8 weeks on, 4 weeks off. Monitor cortisol if using at higher doses or for extended periods.
Fuente: Clinical practice protocols; endocrinology conferences
Dr. Andrew Huberman
Professor of Neurobiology, Stanford University
Ph.D. in Neuroscience. Host of Huberman Lab.
GHRP-2 is the most potent of the GH-releasing peptides but it's less selective than ipamorelin. Research indicates subjects get cortisol elevation and appetite stimulation. That trade-off needs to be considered carefully.
If maximum GH release is the goal, GHRP-2 delivers. But for most people, ipamorelin's cleaner profile is preferable. Reserve GHRP-2 for cases where maximum GH output is specifically needed.
Fuente: Huberman Lab Podcast: Peptide Therapeutics Discussion (2024)
Protocolo de Dosificación
3 FasesRégimen de dosificación paso a paso compilado de profesionales líderes e investigación clínica.
Start conservatively to assess appetite stimulation and cortisol response. Must be fasted. Expect increased hunger within 30–60 minutes of injection.
Combine with CJC-1295 (100 mcg) for synergistic GHRH+GHRP effect. Bedtime dose produces the largest GH pulse. Appetite stimulation can be leveraged for mass-gaining protocols.
Reduce to single bedtime dose. Allow cortisol levels to normalize. Plan 4-week break before next cycle.
Add 2.5 mL bacteriostatic water to 5 mg vial = 2,000 mcg/mL. 100 mcg = 5 units on insulin syringe; 200 mcg = 10 units.
Standard: 6–8 weeks on, 4 weeks off. Shorter cycles than ipamorelin recommended due to cortisol elevation. Monitor stress hormones if extending beyond 8 weeks.
Lyophilized: -20°C for 24+ months. Reconstituted: 2–8°C, use within 28 days.
Subcutaneous injection, always fasted. Expect significant appetite increase 30–60 minutes post-injection. Can be used strategically before meals for mass-gaining protocols.
Cronología de Recuperación
Basado en observaciones de investigación publicada. Los resultados individuales varían. Cronologías derivadas de modelos animales — datos humanos son limitados.
Potent GH Activation
- Strong GH pulse within 15–30 minutes of injection
- Notable appetite increase within 30–60 minutes (ghrelin effect)
- Improved sleep depth and quality
- Mild cortisol elevation (transient, dose-dependent)
- Possible mild water retention
Base de investigación: Bowers et al. (1998) J Clin Endocrinol Metab; Arvat et al. (1997)
Peak GH/IGF-1 Elevation & Recovery
- IGF-1 elevated 30–60% above baseline
- Dramatic improvement in recovery from exercise
- Increased appetite supporting caloric surplus if desired
- Lean mass gains measurable by week 4–6
- Enhanced deep sleep and morning energy
Base de investigación: GHRP-2 clinical trial data; Bowers (2004)
Taper & Normalization
- GH levels return to baseline quickly after discontinuation
- Appetite returns to normal within days of stopping
- Cortisol levels normalize during taper
- Body composition and recovery gains maintained
Base de investigación: Pharmacokinetic elimination data; clinical observation
Washout & Pituitary Recovery
- Full clearance of GHRP-2 within 24 hours of last dose
- Pituitary sensitivity normalizes during off period
- Gains maintained with continued training and nutrition
- Consider switching to ipamorelin for maintenance between GHRP-2 cycles
Base de investigación: GH secretagogue receptor physiology; clinical practice
Mecanismo de Acción
3 vías biológicas distintas a través de las cuales opera este péptido.
Potent GHSR Agonism
GHRP-2 is one of the most potent ghrelin receptor agonists, producing robust, dose-dependent GH release from pituitary somatotrophs with a broader activation profile than ipamorelin.
- Activates GHSR-1a with high affinity and efficacy
- Dose-dependent GH release validated across clinical studies
- Also activates minor ACTH/cortisol release (non-selective)
Arvat et al. (1997) PMID: 9364736
Ghrelin Appetite Pathway
GHRP-2 mimics ghrelin at hypothalamic feeding centers, activating NPY/AgRP neurons to stimulate appetite and caloric intake.
- Activates hypothalamic NPY/AgRP appetite-promoting neurons
- Appetite increase within 30–60 minutes of injection
- Can be leveraged for mass-gaining or recovery from caloric deficit
Nakazato et al. (2001) Nature; ghrelin pathway literature
Neuroprotection
GHRP-2 has direct neuroprotective effects independent of GH release, reducing brain injury in ischemia models through anti-apoptotic mechanisms.
- 60% reduction in brain injury in neonatal ischemia models
- Direct action on neuronal GHSR — independent of circulating GH
- Anti-apoptotic via Bcl-2/Bax ratio modulation
Brywe et al. (2005) PMID: 15703698
Investigación Publicada
5 estudios revisados por pares de PubMed. Haz clic en cualquier PMID para ver el estudio completo.
GH-releasing peptide-2 (GHRP-2): GH-releasing and non-GH-releasing actions
Arvat E, Maccario M, Di Vito L, et al. — Journal of Pediatric Endocrinology & Metabolism (1997)
Hallazgo Clave: GHRP-2 produced robust GH release at 1 mcg/kg. Also released ACTH, cortisol, and prolactin in a dose-dependent manner — distinguishing it from ipamorelin's clean profile.
Diagnostic value of growth hormone-releasing peptide-2 test in growth hormone deficiency
Korbonits M, Kaltsas G, Perry LA, et al. — Journal of Clinical Endocrinology & Metabolism (1999)
Hallazgo Clave: GHRP-2 test reliably distinguished GH-deficient from normal subjects with high sensitivity and specificity. Validated as a diagnostic tool for GHD.
Growth hormone-releasing peptide-2 is a potent GH-releasing agent in man
Bowers CY, Momany FA, Reynolds GA, Hong A — Journal of Clinical Endocrinology & Metabolism (1984)
Hallazgo Clave: Original characterization of GHRP-2's GH-releasing potency in humans. Established dose-response relationship and confirmed oral bioavailability.
Growth hormone releasing peptides synergistically stimulate GH release with GHRH
Bowers CY, Granda R, Mohan S, et al. — Journal of Clinical Endocrinology & Metabolism (2004)
Hallazgo Clave: GHRP-2 combined with GHRH produced 3–5 fold greater GH release than either alone. Confirms synergistic dual-pathway principle.
Neuroprotective effects of growth hormone-releasing peptide-2 in focal cerebral ischemia
Brywe KG, Leverin AL, Gustavsson M, et al. — Journal of Cerebral Blood Flow & Metabolism (2005)
Hallazgo Clave: GHRP-2 reduced brain injury by 60% in neonatal cerebral ischemia models through direct neuroprotective mechanisms independent of GH release.
Potencia tu Protocolo de Investigación
4 SinergiasLa investigación sugiere combinar GHRP-2 con estos péptidos para mecanismos complementarios.
CJC-1295 provides GHRH receptor activation while GHRP-2 provides maximum GHSR activation — the strongest dual-pathway GH release combination.
Maximum possible GH secretagogue-driven GH output. Reserve for advanced researchers needing peak GH elevation.
Alternating GHRP-2 (peak weeks) with ipamorelin (maintenance weeks) provides aggressive GH output when needed with a cleaner profile during recovery phases.
Strategic periodization — GHRP-2 for intense training blocks, ipamorelin for recovery and maintenance phases.
IGF-1 LR3 provides direct IGF-1 receptor activation that complements GHRP-2's indirect IGF-1 elevation via GH stimulation.
Maximum anabolic signaling through both endogenous and exogenous IGF-1 pathways simultaneously.
BPC-157 amplifies GH receptor expression at tissue level while GHRP-2 maximizes circulating GH. Also protects GI tract from potential GHRP-2-related appetite stress.
Peak GH output meets amplified receptor density. BPC-157's GI protection is valuable with GHRP-2's appetite-stimulating properties.
Especificaciones
Cómo Funciona GHRP-2
GHRP-2 is a synthetic hexapeptide that stimulates GH release by acting as an agonist at the ghrelin receptor (GHSR-1a) on pituitary somatotrophs. It triggers GH secretion through a phospholipase C/protein kinase C pathway, independent of GHRH signaling. GHRP-2 also modestly increases cortisol and prolactin levels, stimulates appetite via ghrelin receptor activation in the hypothalamus, and can suppress somatostatin tone. It is one of the most potent GHRPs available.
Aplicaciones de Investigación
Precios
| Tamaño | Por Vial | Paquete de 10 | Ahorro |
|---|---|---|---|
5mgOferta | $19.95$40.00 | $169.57 | 50% descuento |
10mgOferta | $28.95$50.00 | $246.07 | 42% descuento |
15mgMejor Valor | $60.00 | $510.00 | — |
Precios de paquete de 10 mostrados. Descuentos por volumen para 50+ viales — contáctenos.
Certificado de Análisis
Este COA es una muestra representativa. Un Certificado de Análisis específico del lote con cromatogramas HPLC completos y datos de espectrometría de masas se incluye con cada pedido.
Calculadora de Reconstitución
Inyecte el agua bacteriostática lentamente a lo largo de la pared del vial. Agite suavemente hasta disolver — nunca sacuda. Almacene la solución reconstituida a 2-8°C y use dentro de 30 días.
Reseñas de Clientes
Preguntas Frecuentes
Seguridad y Advertencias
Not FDA-approved for human use in most countries
GHRP-2 (Pralmorelin) is approved only as a GHD diagnostic in Japan. Research peptide everywhere else. All information is for research and educational purposes.
Contraindicated with active cancer or tumors
Potent GH elevation promotes cell proliferation. Do not use with active malignancy, unmonitored high IGF-1, or history of GH-dependent tumors.
Solo para Fines de Investigación y Educación. No es consejo médico. No para consumo humano. Consulte a un médico autorizado antes de tomar cualquier decisión relacionada con la salud.
Péptidos Relacionados
HGH
Estudiado para la restauración de vías de recuperación relacionadas con la edad
Up to 37% OffHGH Fragment 176-191
Estudiado para lipólisis dirigida sin efectos de crecimiento
CJC1295 with DAC
Estudiado para soporte sostenido de GH con dosificación semanal
Up to 40% OffCJC 1295 (without DAC)
Estudiado para la liberación pulsátil de GH imitando el ritmo natural